Adverum's Gene Therapy for Wet AMD Earns FDA's RMAT Designation

𝐀𝐝𝐯𝐞𝐫𝐮𝐦’𝐬 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐟𝐨𝐫 𝐖𝐞𝐭 𝐀𝐌𝐃 𝐄𝐚𝐫𝐧𝐬 𝐅𝐃𝐀’𝐬 𝐑𝐌𝐀𝐓 𝐃𝐞𝐬𝐢𝐠𝐧𝐚𝐭𝐢𝐨𝐧.

👏 Adverum Biotechnologies has received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for its gene therapy, lxoberogene soroparvovec (Ixo-vec), aimed at treating wet age-related macular degeneration (AMD). This designation is based on promising early clinical data and could expedite the therapy’s development. Ixo-vec, which uses Adverum’s proprietary AAV.7m8 vector technology, has already shown potential in reducing treatment burden and maintaining vision. The company plans to continue its collaboration with regulators, with updates expected later this year.